WO1998046287A2 - Drug delivery via therapeutic hydrogels - Google Patents
Drug delivery via therapeutic hydrogels Download PDFInfo
- Publication number
- WO1998046287A2 WO1998046287A2 PCT/CA1998/000351 CA9800351W WO9846287A2 WO 1998046287 A2 WO1998046287 A2 WO 1998046287A2 CA 9800351 W CA9800351 W CA 9800351W WO 9846287 A2 WO9846287 A2 WO 9846287A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrogel
- gelatin
- medical device
- liposomal
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/145—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/43—Hormones, e.g. dexamethasone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/432—Inhibitors, antagonists
- A61L2300/436—Inhibitors, antagonists of receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/626—Liposomes, micelles, vesicles
Definitions
- the present invention is directed to an effective drug delivery vehicle involving the containment of a therapeutic agent within a hydrogel, which hydrogel is then bound to a substrate.
- the substrates of the present invention include any indwelling medical device or implant, wound dressings, wound closures, and the like.
- the present invention further provides means for compounding such hydrogels and affixing such hydrogels to a substrate.
- catheter-related septicemia represents the most common life-threatening complication associated with intravascular catheters.
- catheter-site inflammation There is a strong relationship between catheter-site inflammation and the recovery of bacteria from the surface of the device. In situ, the catheter surface becomes colonized with opportunistic microbial pathogens, and these colonies become the source of infections.
- a common source for catheter colonization and catheter-related sepsis is the skin insertion site. Indeed, the skin surface is the most common source of short-term catheter colonization and subsequent infection. Catheter-related infections remain a significant problem in healthcare facilities. It is generally accepted that no method has yet emerged for the adequate and satisfactory management of catheter-related infection.
- the adhesion of microorganisms to the catheter surface is related to the interaction of the host, the microorganisms and the catheter material.
- the host tissue reacts to the catheter material as a foreign body and deposits a thrombin coat over the material, which becomes colonized with microbes, often within 24 hours; this coating of protein and microorganisms is called a biofilm.
- microbes find a suitable niche for continued growth as well as for protection from antibiotics, phagocytic neutrophils, macrophages and antibodies.
- biomedical products that incorporate and release silver compounds for infection control have been studied for many years. However, clinical studies of these products, including catheters, have shown only minor improvements in infection control.
- the devices have been described to exhibit resistance to infection, but in practical application fail to adequately inhibit infection.
- Ciresi et al. 1996 ( Am Surg 62:641-646) compared the incidence of catheter- related infection and catheter-related sepsis between a standard catheter and the recently released ArrowgardTM catheter in a clinical trial with one-hundred-ninety- one patients receiving total parenteral nutrition.
- the ArrowgardTM catheter contains a combination of silver sulfadiazine and chlorhexidine, that is thought to render the catheter surface resistant to bacterial colonization and subsequent sepsis.
- the authors concluded that the coating of the central venous catheters with sulfadiazine and chlorhexidine does not reduce the rate of catheter-related infection or catheter- sepsis when compared with a standard central venous catheter in patients receiving total parenteral nutrition.
- Hasaniya et al. 1996 found that the use of an attachable subcutaneous silver-impregnated cuff failed to decrease the incidence of central venous catheter-related infection and sepsis.
- U.S. Patent No. 4,442,133 there is disclosed a process for vascular prostheses with a cationic surfactant, e.g. tridodecylmethyl-ammonium chloride (TDMAC), to increase sites for antibiotic bonding.
- a cationic surfactant e.g. tridodecylmethyl-ammonium chloride (TDMAC)
- TDMAC tridodecylmethyl-ammonium chloride
- U.S. Patent No. 4,749,585 provides a method for coating a prosthesis with an ionically charged surfactant and an antibiotic compound encapsulated within phospholipid vesicles, wherein said vesicles have a surface charge opposite to that of said surfactant.
- the drawback of this system is that the amount of liposomes coated on to the surface is generally low, not allowing for a therapeutic dose of drug to be retained on the device for periods of time necessary to suppress or alleviate the infection.
- Second, upon insertion of a device, such as a catheter so treated it is expected that the surface coating of ionically bound liposomes will be sheared off from the area where the liposomes were intended to reside.
- Wachol-Drewek et al. 1996, Biomaterials 17:1733-1738 disclose the use of collagen implants of various structures and a gelatin sponge which were placed in antibiotic solutions and allowed to absorb the compounds. They concluded: "If an implant that has a protective effect against wound infections over a period of 24-48 h is required, the materials described here are suitable. However, where treatment in infected areas should ensure antibiotic cover for 5-10 d[days] neither collagen materials immersed in antibiotics nor collagen sponges containing gentamicin are suitable.” Several studies have used photoactivated surface modification in attempts to improve the biocompatibility of biomedical devices.
- Photoreactive surface modification of fabricated devices is described in Matsuda & Inoue 1990 (Trans Am Soc Artif Intern Organs, Poster Session 1, Biomaterials, pp. M161-M164).
- Nakayama & Matsuda 1992 (AS AIO Journal 38:M421-424) describe the incorporation of heparin, useful as a thromboresistant molecule, within a hydrophilic co-polymer of poly(N,N-dimethylacrylamide)- poly(2-cinnamoylethyl methacrylate) linked to a polyethylene terephthalate surface using a photochemical process; poly(m-azidostyrene) was initially applied to the polyethylene terephalate surface to provide a reactive interface.
- the type of drug incorporated into the hydrogel formulation is not restricted to any single antibiotic, or combination of one or more of these.
- the hydrogel composition might comprise a variety of active agents including antibiotics, hormones, growth factors and other factors that are beneficial for the condition under management, in accordance with sound medical judgement.
- the present invention avails the use of antibiotic-loaded liposomes sequestered within a biocompatible hydrogel retained on the surface of the biomedical device, e.g. catheter.
- Liposomes, microspheres, nanospheres, biodegradable polymers, and other systems are excellent drug delivery vehicles; and the methods of preparation and drug loading procedures for liposomes and the others are well-known in the art.
- Liposomes can store both apolar and polar compounds via interactions with the biocompatible and biodegradable lipid bilayer, or compartmentation within the aqueous core, respectively.
- a method for producing a biofilm-resistant surface might involve the binding of antibiotic-containing liposomes directly to the surface.
- Theoretical calculations indicate that if a surface was saturated with drug-carrying liposomes, only about 150 ng of the antibiotic ciprofloxacin could be localized per square centimeter of surface. Nanogram quantities of ciprofloxacin are unlikely to provide protection from microbes over substantial periods of time, e.g. several days or more.
- liposome bilayer allows for drug release over a period ranging from days to weeks. See, e.g., R. Nicholov, V. DiTizio, and F. DiCosmo, "Interaction of paclitaxel with phospholipid bilayers," J. Lipo. Res., 5, 503-522 (1995). M. S. Webb, T. O. Harasym, D. Masin, M. B. Bally, and L. D. Mayer, "Sphingomyelin-cholesterol liposomes significantly enhance the pharmokinetic and therapeutic properties of vincristine in murine and human tumour models," Br. J. Cancer, 72, 896-904 (1995). Furthermore, the biocompatibility of liposomes ensures that they will be safely degraded and assimilated by the host after their supply of drug is exhausted after six days or more.
- the method of the present invention provides for co-valently attaching liposomes to a substrate such as a catheter, or other liquid-flow conduit, or other device, such as a wound dressing.
- the method exploits the surface area of the device as well as the volume occupied by the hydrogel matrix bonded to the surface.
- the volume of gel matrix can accommodate large quantities of drug-loaded liposomes, microspheres, nanospheres, or other drug carrier and consequently, relatively high doses of a therapeutic drug can be deposited at specific sites.
- the hydrogel matrix is biocompatible and biodegradable (i.e.
- the containment of the liposomes within the gel matrix also creates an opportunity to control drug diffusion rates, thereby affording long-term drug efflux.
- the present invention includes a method for loading efficacious quantities of a liposomal therapeutic agent on a medical device by mixing said liposomal therapeutic agent with a hydrogel, and covalently binding said hydrogel to a pre-formed polymeric surface of a medical device.
- pre-formed polymeric surface is meant that the polymeric material used in fabricating the medical device is formed or manufactured in advance of the covalent attachment of the hydrogel.
- covalent attachment of the hydrogel to the polymeric material can be effected through the use of a bifunctional linker molecule, preferably one comprising an azide functional group.
- the pre-formed polymeric surface is a silicone rubber.
- One such embodiment is a silicone catheter loaded with a co-valently bonded polyethylene glycol-gelatin matrix containing a liposomal antibiotic-carrier coating to control catheter-related infections, such as bacteriuria and septicemia.
- Medical devices where the coating can be used include catheters, wound closures, surgical dressings, temporary orthopedic implants and others.
- the liposomal hydrogel of the present invention includes a variety of hydrogel drug combinations. Generally, the selection or pairing of the hydrogel and drug is determined only by the desired application and relevant indication. That is, any active agent that can be compounded into liposomes, microspheres, nanospheres, or other suitable encapsulation vehicle can be confined within the hydrogel matrices of the present invention to create the therapeutic hydrogels of the present invention. Those hydrogels can then be affixed to a substrate such as the surface of a catheter or other in-dwelling liquid conduit, or the substrate or matrix of a wound closure or wound dressing material.
- One embodiment of the present invention involves the deposition and covalent attachment of a polyethylene glycol-gelatin matrix layer to the surface of indwelling biomedical implants (e.g. catheters, stents, intravenous tubes, dialysis tubes, orthopedic implants, surgical sponges and wound dressings, etc.) and the sequestration or co-valent attachment of liposomes to the constituents of the matrix.
- the liposomes contain a therapeutic.
- the matrix thus constitutes a vehicle for the containment of high concentrations of therapeutic agent such as one or more antibiotics, hormones, steroids, growth factors, antihistamines, colony stimulating factors, interleukins, and the like, and/or combinations thereof.
- the therapeutic hydrogels of the present invention can be used in the management of tissue and biomaterial associated infection.
- the matrix can be a hydrogel (e.g., gelatin, pectin, etc.), a protein (e.g. collagen, hemoglobin, etc.), or other adjuvant.
- the matrix will have some structural integrity as by cross-linking or similar structural support to impart resistance to shear forces resulting from insertion of the device.
- the present invention provides a medical device having a polymeric substrate; a matrix material covalently bound to said substrate; and a liposomal therapeutic agent confined within said matrix material.
- the matrix material can be a hydrogel, a protein, or other suitable adjuvant.
- the matrix material will preferably be a cross-linked material.
- One example is gelatin cross-linked with polyethylene glycol as by reacting gelatin with bis-(amine)-PEG.
- Matrix material can be covalently bound to a substrate by a variety of means.
- a protein such as gelatin can be derivatized with a bifunctional linker molecule such as 4-azido-2,3,5,6-tetrafluorobenzoic acid. That is, the carbonyl carbon of the benzoic acid group can be made to react with a free amine of a protein to form an amide; the azido functionality can be made to react with a methylene carbon of the silicone rubber. In this manner, the matrix material is covalently bonded to the substrate.
- a bifunctional linker molecule such as 4-azido-2,3,5,6-tetrafluorobenzoic acid. That is, the carbonyl carbon of the benzoic acid group can be made to react with a free amine of a protein to form an amide; the azido functionality can be made to react with a methylene carbon of the silicone rubber. In this manner, the matrix material is covalently bonded to the substrate.
- the therapeutic hydrogels of the present invention serve as support material for a variety of liposomal therapeutics.
- Any therapeutic agent suitable for encapsulation in a liposome, microsphere, nanosphere or the like can be utilized in the present invention.
- therapeutic agents useful in the present invention include antibiotics, antihistamines, hormones, steroids, therapeutic proteins, and the like. It will be appreciated by those of ordinary skill in the art that the desired concentration of active agent within a hydrogel loaded on a substrate will vary depending upon the characteristics of the chosen active agent. For example, as between an antibiotic and a therapeutic protein, the required concentration of antibiotic, which are generally active in the microgram range, will likely be higher than the concentration of a therapeutic protein, many of which are active in the nanogram range.
- a preferred embodiment of the present invention is a gelatin hydrogel cross- linked with polyethylene glycol (PEG); and dispersed within the hydrogel is a liposomal antibiotic such as ciprofloxacin.
- PEG polyethylene glycol
- Ciprofloxacin has been shown to exhibit good activity against a broad spectrum of bacteria, particularly those associated with urinary tract infections.
- Such embodiments provide dramatically improved in-dwelling medical devices.
- Medical devices of the present invention can be loaded with as much as 1000 ⁇ g/cm 2 ciprofloxacin.
- Preferred embodiments have about 10 - 300 ⁇ g/cm 2 ; and still more preferred embodiments have about 25 - 200 ⁇ g/cm 2 .
- the present invention avails long-term, slow release of an anti-infective active agent from an indwelling medical device; and dramatically reduces the frequency with which such in-dwelling medical devices must be removed and replaced.
- the PEG-gelatin-liposome mixture can be effectively applied to the surface of a silicone Foley catheter that has been pre-treated with phenylazido-modified gelatin. Methods for immobilization of photoreactive gelatin on the catheter's surface are presented herein. Use of silicone devices is not a limiting feature, as any such polymeric device can be treated to harbor a hydrogel in which liposomes, or other drug carriers are sequestered.
- the present invention provides a method for associating substantial quantities of antibiotic-releasing liposomes with a silicone Foley catheter through their inclusion in a surface-coating of PEG-gelatin hydrogel covalently linked to the silicone surface, and the antibiotic was released to the surrounding area over a period of greater than five days.
- Modifications of the technique should allow it to be applied to other medical devices as well, such as, intraperitoneal catheters, joint and vascular prostheses, and reconstructive implants.
- An attractive feature of this system is the possibility of sustained release of compounds having a range of chemical properties, such as antibiotics, enzymes, growth factors, human hormones, anticoagulants, etc.
- the surface characteristics of the PEG-gelatin hydrogel will improve biocompatibility of the device as hydrogel-coated catheters tend to minimize the inflammation associated with the presence of any foreign object in the body.
- J. N. Nacey and B. Delahunt "Toxicity study of first and second generation hydrogel-coated latex urinary catheters," Br. J. Urol, 67:314-316 (1991).
- the inclusion of gelatin in our hydrogel system will lead to its eventual degradation in vivo leaving a co-valently-bonded surface layer of AFB-gelatin that should be relatively resistant to further protease digestion.
- T. Okada and Y. Ikada "In vitro and in vivo digestion of collagen covalently immobilized onto the silicone surface," J.
- the liposomal matrix materials of the present invention can be used to prevent or treat patients at risk of or suffering from biofilm mediated infection or other forms of infection associated with in-dwelling medical devices, wound closures, and the like.
- the method comprises inserting into a patient a medical device of the present invention, said medical device comprising a substrate, as for example, a silicone rubber substrate, and covalently bound to said substrate is a hydrogel within which is dispersed a liposomal therapeutic material such as an antibiotic.
- the method comprises replacing infected medical devices with the medical devices of the present invention.
- hydrogel or gel any material forming, to various degrees, a jellylike product when suspended in a solvent, typically water or polar solvents.
- a solvent typically water or polar solvents.
- These gels can be proteins such as collagen or hemoglobin, or more conventional hydrogels such as gelatin, pectin, and fractions and derivatives thereof.
- liposomal therapeutic agents is meant any physical structure surrounding or encapsulating a therapeutic agent such as a drug.
- liposomal therapeutic agents will include various drugs or biologically active agents such as antibiotics, antihistamines, hormones, steroids, growth factors, colony stimulating factors, interleukins, and the like confined or encapsulated within a structure such as a liposome, whether of unilamellar or bilayer structure, or microspheres or nanospheres or the like.
- a bifunctional linker molecule is any molecule possessed of at least two functional groups that can chemically react with and form covalent bonds with other functional groups or chemical substituents such as the free amines of proteins and the like.
- the bifunctional linker will have an aryl amine functionality, as in an aroyl azide group, and a carbonyl functionality, as in a carboxylic acid group.
- NHS-AFB was prepared as described in J. F. W. Keana and S. X. Cai, "New reagents for photoaffinity labeling and photolysis of functionalized perfluorophenyl azides," J. Org. Chem., 55:3640-3647 (1990) using the coupling agent DCC.
- AFB- gelatin of varying degrees of substitution was synthesized by the addition of NHS-
- the degree to which gelatin's amino groups reacted with NHS-AFB was determined. In brief, 20 g of gelatin or AFB-gelatin in 1.5 mL of 50 mM Na 2 P0 buffer (pH 8.0) was used. While mixing the protein solution using a vortex agitator, 0.5 mL of fluorescamine in dioxane (1.1 mM) was added and mixing continued for 15 seconds.
- Gelatin was iodinated using Iodo Beads (Pierce, Rockford, IL) according to the supplier's directions.
- Iodo Beads Pierce, Rockford, IL
- 100 ⁇ g of gelatin 500 ⁇ L of 0.2 mg/mL gelatin in Hepes buffered saline, pH 7.4 (HBS)
- HBS Hepes buffered saline
- Na 1 5 I (1 mCi from Amersham Canada, Oakville, ON
- the reaction vial was washed with three 0.5 mL aliquots (200 ⁇ g/mL) of unlabeled gelatin.
- the protein solution (approx. 400 ⁇ g in 2.1 mL of HBS) was dialyzed in 200 mL of buffer until the dialysate was minimally radioactive (approx. 48 hrs with 5 changes of medium).
- the specific activity of the iodinated gelatin was determined by a technique that exploits the insolubility of the complex formed between gelatin and the dye Sirius Red in acetic acid Four 50 ⁇ L aliquots were removed from the iodinated protein solution and added to 1.5 mL polypropylene centrifuge tubes, followed by the addition of 50 ⁇ L of HBS and 1 mL of Sirius Red (50 ⁇ M) in 0.5 M acetic acid.
- the tubes were incubated at room temperature for 30 minutes and subsequently centrifuged at 12,000 x g for 30 minutes. The supernatant was removed and a portion (0.5 mL) was used for protein quantitation via the decrease in absorbance (540 nm) of the dye remaining in solution.
- the protein/dye pellet was resuspended with three 150 ⁇ L washes of 0.2 N NaOH containing 2 mg/mL gelatin. The radioactivity of the eluate was measured in a liquid scintillation counter. Control experiments indicated that the presence of Sirius Red in the scintillation fluid did not interfere with the determination of I radioactivity.
- Residual adsorbed protein was measured by cutting the centrifuge tubes into quarters and placing them in scintillation vials for counting. The specific activity was calculated to be 0.12 ⁇ 0.01 ⁇ Ci/ ⁇ g. This level of labeling is consistent with the paucity of tyrosine and histidine residues in gelatin.
- Radioiodinated gelatin was modified with AFB as described above, however, the coupling solution and dialysis medium consisted of HBS (pH 8.0 and 7.4, respectively). The ratio of NHS-AFB to gelatin in the coupling solution was 1 :4 (w/w). Following dialysis, the volume of the AFB-( I)gelatin solution was made up to 5 mL and the protein concentration was determined to be 3.9 ⁇ 0.6 ng/ ⁇ L.
- Liposomes were composed of DPPC/Cholesterol/PEG-DSPE/Rhodamine- DPPE in a 1 : 1 :0.05:0.001 ratio.
- the formulation to be used is not limiting, and any number of lipid-to- other-constituents ratios may be used to effectively achieve the embodiments of this invention.
- the lipids were dissolved in 4 mL of chloroform and the solvent was removed in vacuo. The resulting lipid film was placed under vacuum for two hours and subsequently hydrated with 1 mL of 250 mM ammonium sulfate (pH 2.5) at 45 °C.
- Liposomes were then frozen in liquid nitrogen and thawed in a 45 °C water bath (5X), followed by high-pressure extrusion through two 100 nm-pore membranes (10X). This procedure has been shown to produce unilamellar liposomes with an average diameter of 100 nm and an equal solute distribution between the exterior and interior of the liposomal membrane.
- 5X 45 °C water bath
- P. R. Cullis "Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential," Biochim. Biophys. Ada, 812:55-65 (1985); L. D. Mayer, M. J.
- PEG-gelatin solutions consisted of 10 % gelatin, 6 % NP-PEG and 10 % sucrose at pH 4.0. If liposomes were required, they were added from a pure liposome suspension. The concentration of liposomes in PEG-gelatin solutions was 15 mM with respect to DPPC. All solutions were heated at 45 °C for 15 min. to dissolve gelatin.
- the PEG-gelatin matrix was also crosslinked by the formation of amide bonds between bis-(amine)-PEG and the free carboxyl groups of gelatin.
- the silicone catheter surface is immersed in a solution of aqueous soluble carbodiimide (2 mg/mL) and incubated at room temperature for 30 min.
- the reaction of the activated carboxyl groups with PEG and gelatin amino moieties is initiated by submersing the silicone material in borate buffer (200 mM, pH 8.5). Incubation in the alkaline buffer proceeds for 2 hr.
- the silicone surface is placed in 10 % sucrose solution for 6 hr, with three changes of medium, to remove non-crosslinked material.
- catheter pieces are spin-coated with 60 ⁇ L of fluid PEG-Gelatin or PEG-gelatin-liposome mixture and incubated at 4°C for 15 minutes. Incubation may occur at temperatures from 4-10°C.
- Gels were polymerized by submersing catheter sections in 200 mM Borate buffer (pH 8.5) for 1 hr. Residual p-nitrophenol was leached from the gels by incubation at room temperature in 10% sucrose (pH 4.0) for
- Liposomes in suspension and those entrapped within PEG-gelatin gels were loaded with ciprofloxacin (Bayer, Leverkusen, Germany) according to the remote- loading technique described in Y.K. Oh, D. E. Nix, and R. M. Straubinger,
- Dehydrated hydrogels were prepared by drying coated catheter sections in an oven at 35°C for 2.5 hr. The dried gels were then rehydrated in Tris buffer (10 mM
- the quantity of therapeutic agent loaded on the substrate can be increased or decreased over greater ranges than those shown in Table I. Greater concentrations of therapeutic agent can be loaded by increasing the amount of drug encapsulated and mixed into the hydrogel. For example, we expect that concentrations up to about 1,000 ⁇ g (1.0 mg) per cm 2 or more of an antibiotic active agent can be loaded on substrates with the methods of the present invention; and that concentrations of up to about 10,000 ⁇ g/cm 3 or more can be loaded on substrates. A preferred concentration range of antibiotic loaded on such substrates is about 10 - 1,000 ⁇ g/cm 2 . A preferred range for ciprofloxacin is about 10 - 200 ⁇ g/cm 2 .
- quantities of therapeutic agent can be increased by increasing the quantity of gel immobilized on the surface of the substrate.
- hydrogel layers of about 0.5 - 10 mm thick can be loaded on substrates to effect the desired drug delivery and therapeutic results; preferred layers are in the range of about 1 - 5 mm; and especially preferred layers are about 2 - 4 mm.
- the release experiment was initiated by placing each catheter section or dialysis membrane (containing liposome suspension 2.7 mM in DPPC) into separate liquid scintillation vials filled with 15 mL of Tris buffer. At selected time intervals 3 mL was removed from each vial for ciprofloxacin quantitation via a fluorescence- based assay using an excitation wavelength of 324 nm, an emission wavelength of 450 nm, and 5 nm slit widths. The amount of ciprofloxacin present was determined by comparisons to a standard curve. The remaining solution in the vials was emptied and replaced with 15 mL of buffer. The samples were incubated at 37 °C throughout the experiment.
- Bacterial biofilm formation assay A clinical isolate of Pseudomonas aeruginosa obtained from a patient with peritonitis was used for all challenge assays.
- An 18 h nutrient broth culture was prepared from a primary isolate maintained at -70 °C in a 50 % (v/v) glycerol- phosphate buffered saline (PBS) solution.
- Catheter sections were aseptically placed in 100 mL of sterile nutrient broth (Difco, Detroit, MI) contained within a 250 mL glass beaker. Twelve catheter sections from each coating formulation were added to individual beakers. The P.
- aeruginosa culture was washed 3 times in a pH 7.1 PBS solution, then inoculated to each of the beakers.
- the inoculum size was sufficient to yield 1.5 ⁇ 0.5 x 10 cfu/mL in the 100 mL volume.
- the inoculated catheter suspensions were then placed in an incubator maintained at 37 °C and agitated at a rate of 100 rpm.
- One half of the 100 mL volume was aseptically removed from each beaker and replaced with a like volume of sterile nutrient broth on a daily basis.
- triplicate catheter sections were removed from each of the beakers and viable bacteria were recovered from the catheter surfaces as described below. The number of viable bacteria in nutrient broth samples was also determined.
- the catheter sections were removed from the bacterial suspensions and individually rinsed with a 10 mL volume of sterile PBS delivered via a gravity feed from a 10 mL pipet.
- the rinsed sections were placed in 20 mL plastic test tubes containing 5 mL volumes of sterile PBS and 3 mm diameter glass beads.
- the catheter sections were vortexed for 1 minute at high speed. The sonication and vortexing procedure was repeated three times. Aliquots were then removed from each of the suspensions and plated to nutrient agar. The plates were incubated at 37 °C for
- the modification of the silicone catheter surface in this example used the photoreactive molecule 4-azido-2,3,5,6-tetrafluorobenzoic acid (AFB). It can be linked to the amino groups of gelatin via N-hydroxysuccinimide (NHS) chemistry. Based on the amino acid composition of ox hide gelatin, (J. E. Eastoe and A. A. Leach, "Chemical constitution of gelatin,” in Science and Technology of Gelatin, A. G. Ward and A. Courts (eds.), Academic Press, New York, 1977, pp. 73-107) the typical gelatin molecule (MW 75,000) contains approximately 25 e-amino groups derived from lysine and hydroxylysine.
- AZA 4-azido-2,3,5,6-tetrafluorobenzoic acid
- Ciprofloxacin release rates were determined for the following samples: liposomes-only, PEG-gelatin hydrogel alone, a liposomal PEG-gelatin hydrogel, and a drug-containing liposomal hydrogel that was air dried and then rehydrated with pH 7.4 Tris buffer. All the liposomes used in this study contained DPPC and cholesterol. PEG-lipid was also included to avoid gelatin-induced destabilization of the bilayer and to increase immobilization of the liposomes within the hydrogel matrix via stearic interactions. The results of the experiment are summarized in Figure 2. The quantity of ciprofloxacin released at a given time point is expressed as a percentage of the total amount released throughout the experiment. There are two notable trends. The hydrogel-only, and rehydrated liposomal hydrogel treatments were not successful in retaining ciprofloxacin for a sustained period of time; almost all of the drug initially incorporated was released within the first two hours.
- the dried liposomal hydrogel i.e., dried prior to being loaded with antibiotic, was found to maintain its sustained release properties after rehydration and is an important consideration for the clinical application of the system.
- An effective drying and rehydration process uses the dried liposomal hydrogel rehydrated in a solution containing 25 mg of ciprofloxacin.
- a dried hydrogel containing no liposomes was hydrated in a 25 mg/mL ciprofloxacin solution.
- the total average amount of antibiotic entrapped within these hydrogels is listed in Table 2, and for comparative purposes the total entrapped drug is also included.
- hydrogels rehydrated in concentrated ciprofloxacin solution retained very large quantities of antibiotic (approx. 1.4 mg/ 1 cm catheter section). Almost all (>99%) of the hydrogel-associated ciprofloxacin was released after the first four hours of incubation, as expected from an analysis of the prior art.
- the optimal efflux profile in terms of prolonged release of substantial antibiotic quantities was obtained from liposomal hydrogel samples that were not dehydrated.
- the hydrogel system was shown to be capable of releasing substantial quantities of drug for up to 7 days. It is possible to improve the amount and duration of release by increasing the concentration of liposomes within the hydrogel; this aspect is not limiting. For example, the concentration can be at least doubled without affecting hydrogel stability. Increasing the liposome concentration allows the air dried liposomal hydrogel system to become a viable alternative as this compensates for the decrease in drug encapsulation efficiency associated with the in situ generation of liposomes. Alternatively, a dried liposomal hydrogel with suitable sustained release properties as presented here may be obtained by the development of a lyophilization protocol.
- a practical aim of this invention is toward a catheter, or any polymeric biomedical device coating capable of resisting colonization by bacteria and subsequent infection in vivo and during application.
- untreated, PEG-gelatin coated, and ciprofloxacin-containing liposomal hydrogel catheter sections were challenged with a clinical strain off. aeruginosa known to form biofilms on silicone catheters.
- the hydrogel coating containing antibiotic liposomes was effective in preventing cells from adhering and remaining viable.
- the number of viable bacteria in the broth containing these sections was approximately 6.7 x 10 cfu/mL at the end of the experiment.
- DPPC dipalmitoylphosphatidylcholine
- PEG-DSPE PEG- distearoylphosphatidylethanolamine
- rhodamine-DPPE 4-azido-2,3,5,6-tetrafluorobenzoic acid
- ARB 4-azido-2,3,5,6-tetrafluorobenzoic acid
- Porcine gelatin-a MW 50,000-100,000
- NP-PEG polyoxyethylene bis(p-nitrophenyl carbonate)
- NP-PEG polyoxyethylene bis(p-nitrophenyl carbonate)
- cholesterol were obtained from Sigma (St. Louis, MO).
- Fluorescamine, 1,3-dicyclohexylcarbodiimide (DCC), N-hydroxysuccinimide (NHS), and Sirius Red were purchased from Aldrich (Milwaukee, WI). All reagents and solvents were of analytical grade and were used without further purification.
- Silicone Foley catheters (Sherwood Medical, St. Louis, MO) were prepared for use by sectioning into cylinders (3 mm diameter and 10 mm length). The open ends of the sections were sealed with silicone rubber (RTV 108, GE, Pickering, ON). Occasionally, cylindrical sections were further subdivided into rectangular pieces (5 mm x 3 mm). Silicone sections were cleaned prior to each experiment by refluxing in methanol for six hours.
- Two pediatric silicone Foley catheters were coated with a PEG-gelatin- liposome composition of the present invention as described herein, under aseptic conditions.
- the catheters were inserted into the urethra of two male New Zealand white rabbits. After ten minutes the catheters were removed; and the catheters and excised urethra were examined. No disruption of the gel was observed on the catheter, and no gel fragments were detected in the urethra.
- the surface of polydimethylsiloxane (PDMS) polymers, and polymers such as iso-butylene, cis-l,4-isoprene, trans-l,4-isoprene, polyethylene and the like can be photochemically modified.
- the method uses the photoreactive molecule benzoylbenzoic acid (BBA), acrylic acid, and PDMS. In the presence of longwave ultraviolet light 320-380 nm BBA is converted to a highly reactive free radical.
- the free radical when in proximity to a polymer such as PDMS is capable of extracting a hydrogen atom from the methylene group of PDMS, without changing the bulk properties of the polymer, and generating a methylene radical with the reformation of BBA.
- a polymer such as PDMS
- the methylene radical induces grafting of AA to the PDMS and polymerization of A A moieties, thus yielding PDMS grafted with polyacrylic acid (PDMS-g-AA).
- the technique can be applied to vinyl monomers; thus polyvinylacetate may be grafted to PDMS, or other material containing a methylene hydrogen. See example 1.
- Gelatin gels may be cross-linked with l-ethyl-3 (3-dimethylamino-propyl) carbodiimide (ED AC) to produce a gel that is stable to at least 50 °C. Prior to cross-linking said gelatin gels may be homogeneously mixed with a suspension of liposomes to act as drug reservoirs.
- the cross-linking chemistry involves the activation of the gelatin carboxyl groups by EDAC.
- the EDAC-gelatin bond in susceptible to aminolysis by the e-amino moieties of the gelatin lysine residues, resulting in cross-linking of the gelatin molecules. This reaction is applicable to any molecules containing carboxyl and amino groups.
- gelatin gels may be crosslinked to poly-AA and or polyethyleneglycol terminated with amino or carboxyl moieties. See example 2.
- a portion of PDMS is incubated in a methanol solution of 100 mM BBA for 1 hour.
- the PDMS sample is removed from the solution and air-dried at 40 °C. for 1 hour.
- the BBA-coated polymer is subsequently placed in a saturated, aqueous solution of
- PDMS-g-AA PDMS grafted with AA
- Gelatin gels are prepared as described in the CIP. Gelatin gels containing liposomes, 40 mg CPPC/mL of 10% gelatin solution are solidified at 4°C. for 15 minutes and placed in a pH 4.5 EDAC (10 mg/mL) solution containing a small amount (1/15 mole fraction of EDAC solution to increase the efficiency of carboxyl group activation) of N-hydroxysuccinimide for 30 minutes at room temperature (20- 25°C). The gels are then cross-linked in a solution of pH 9.0 borate buffer for 1 hour.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98916701A EP0984798B1 (en) | 1997-04-15 | 1998-04-15 | Drug delivery via therapeutic hydrogels |
AT98916701T ATE305803T1 (en) | 1997-04-15 | 1998-04-15 | RELEASE OF ACTIVE INGREDIENTS USING THERAPEUTIC HYDROGELS |
AU70198/98A AU736584B2 (en) | 1997-04-15 | 1998-04-15 | Drug delivery via therapeutic hydrogels |
CA002286644A CA2286644C (en) | 1997-04-15 | 1998-04-15 | Drug delivery via therapeutic hydrogels |
JP54333498A JP2001523124A (en) | 1997-04-15 | 1998-04-15 | Delivery of drugs by therapeutic hydrogel |
DE69831802T DE69831802T2 (en) | 1997-04-15 | 1998-04-15 | ACTIVE INGREDIENT RELIEF THROUGH THERAPEUTIC HYDROGEL |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/843,342 | 1997-04-15 | ||
US08/843,342 US6132765A (en) | 1996-04-12 | 1997-04-15 | Drug delivery via therapeutic hydrogels |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998046287A2 true WO1998046287A2 (en) | 1998-10-22 |
WO1998046287A3 WO1998046287A3 (en) | 1999-02-11 |
Family
ID=25289698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1998/000351 WO1998046287A2 (en) | 1997-04-15 | 1998-04-15 | Drug delivery via therapeutic hydrogels |
Country Status (8)
Country | Link |
---|---|
US (4) | US6132765A (en) |
EP (1) | EP0984798B1 (en) |
JP (1) | JP2001523124A (en) |
AT (1) | ATE305803T1 (en) |
AU (1) | AU736584B2 (en) |
CA (2) | CA2286644C (en) |
DE (1) | DE69831802T2 (en) |
WO (1) | WO1998046287A2 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999049908A1 (en) * | 1998-03-31 | 1999-10-07 | University Of Cincinnati | Temperature controlled solute delivery system |
WO2001015750A1 (en) * | 1999-08-27 | 2001-03-08 | Department Of National Defence | Hydrogel wound dressing containing liposome-encapsulated therapeutic agent |
WO2001089595A1 (en) * | 2000-05-24 | 2001-11-29 | Research & Development Center Of Bioengineering Gmbh | Polymer surface having biologically active properties and methods for the production thereof |
WO2002070022A2 (en) * | 2001-02-28 | 2002-09-12 | Uroteq Inc. | Method of making anti-microbial polymeric surfaces |
WO2002074355A1 (en) * | 2001-03-15 | 2002-09-26 | Dot Gmbh | Calcium phosphate materials containing active ingredients |
WO2003061715A1 (en) * | 2002-01-22 | 2003-07-31 | Pharmacia & Upjohn Company | Infection-resistant medical devices |
EP1553899A2 (en) * | 2002-10-22 | 2005-07-20 | The Biomerix Corporation | Method and system for intravesicular delivery of therapeutic agents |
WO2007110767A2 (en) * | 2006-03-24 | 2007-10-04 | Universita' Degli Studi Di Pavia | Interactive dressings for treatment of dermatological diseases |
US7615593B2 (en) | 2001-04-23 | 2009-11-10 | Wisconsin Alumni Research Foundation | Bifunctional-modified hydrogels |
KR100994543B1 (en) * | 2001-02-16 | 2010-11-16 | 아스텔라스세이야쿠 가부시키가이샤 | 506 implants with fk506 |
US8354123B2 (en) | 2004-09-30 | 2013-01-15 | Covalon Technologies Inc. | Non-adhesive elastic gelatin matrices |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
US9592324B2 (en) | 2006-11-06 | 2017-03-14 | Atrium Medical Corporation | Tissue separating device with reinforced support for anchoring mechanisms |
US9682175B2 (en) | 2004-09-28 | 2017-06-20 | Atrium Medical Corporation | Coating material and medical device system including same |
US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
US9801913B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Barrier layer |
US9844611B2 (en) | 2005-09-28 | 2017-12-19 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
US10322213B2 (en) | 2010-07-16 | 2019-06-18 | Atrium Medical Corporation | Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
US10772995B2 (en) | 2004-09-28 | 2020-09-15 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US10814043B2 (en) | 2004-09-28 | 2020-10-27 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
Families Citing this family (208)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
US8177762B2 (en) | 1998-12-07 | 2012-05-15 | C. R. Bard, Inc. | Septum including at least one identifiable feature, access ports including same, and related methods |
WO2000043539A2 (en) * | 1999-01-25 | 2000-07-27 | Biochip Technologies Gmbh | Immobilization of molecules on surfaces via polymer brushes |
US7892532B2 (en) * | 1999-04-30 | 2011-02-22 | Warsaw Orthopedic, In Emory University | Intracellular delivery of osteoinductive proteins and peptides |
CA2377371A1 (en) * | 1999-06-22 | 2000-12-28 | David N. Herndon | Enhanced wound coverage to enhance wound healing |
US6738661B1 (en) * | 1999-10-22 | 2004-05-18 | Biosynergetics, Inc. | Apparatus and methods for the controllable modification of compound concentration in a tube |
WO2001066167A2 (en) * | 2000-03-03 | 2001-09-13 | Chuter Timothy A M | Large vessel stents and occluders |
US6613082B2 (en) * | 2000-03-13 | 2003-09-02 | Jun Yang | Stent having cover with drug delivery capability |
US6800298B1 (en) * | 2000-05-11 | 2004-10-05 | Clemson University | Biological lubricant composition and method of applying lubricant composition |
US20040018228A1 (en) * | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
WO2002057424A2 (en) * | 2001-01-17 | 2002-07-25 | Zycos Inc. | Nucleic acid delivery formulations |
US20060089721A1 (en) * | 2001-01-17 | 2006-04-27 | Muhanna Nabil L | Intervertebral disc prosthesis and methods of implantation |
EP1359952A1 (en) * | 2001-02-07 | 2003-11-12 | EFMT Entwicklungs- und Forschungszentrum Für Mikrotherapie GmbH | Dynamic implant coatings |
US20110212152A1 (en) * | 2001-02-28 | 2011-09-01 | Ditizio Valerio | Modified anti-microbial surfaces, devices and methods |
EP1372739A4 (en) * | 2001-03-08 | 2005-10-19 | Targesome Inc | Stabilized therapeutic and imaging agents |
US20050276858A1 (en) * | 2001-04-23 | 2005-12-15 | Kao Weiyuan J | Bifunctional-modified hydrogels |
DE50103887D1 (en) * | 2001-07-20 | 2004-11-04 | Peter Hildebrandt | Urological implant |
DE10137102A1 (en) * | 2001-07-30 | 2003-02-27 | Deutsches Krebsforsch | Polyvalent vaccine against diseases caused by papillomaviruses, processes for their production and their use |
US20030064965A1 (en) * | 2001-10-02 | 2003-04-03 | Jacob Richter | Method of delivering drugs to a tissue using drug-coated medical devices |
JP2005518827A (en) * | 2001-10-05 | 2005-06-30 | サーモディクス,インコーポレイテッド | Particle fixing coating and use thereof |
US20030100830A1 (en) * | 2001-11-27 | 2003-05-29 | Sheng-Ping Zhong | Implantable or insertable medical devices visible under magnetic resonance imaging |
US7488313B2 (en) * | 2001-11-29 | 2009-02-10 | Boston Scientific Scimed, Inc. | Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment |
US20040147466A1 (en) * | 2002-01-17 | 2004-07-29 | Barman Shikha P. | Nucleic acid delivery formulations |
TW200304385A (en) * | 2002-03-13 | 2003-10-01 | Novartis Ag | Materials containing multiple layers of vesicles |
US20040267355A1 (en) * | 2002-04-30 | 2004-12-30 | Neal Scott | Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment |
ATE515277T1 (en) | 2002-05-24 | 2011-07-15 | Angiotech Int Ag | COMPOSITIONS AND METHODS FOR COATING MEDICAL IMPLANTS |
US8313760B2 (en) | 2002-05-24 | 2012-11-20 | Angiotech International Ag | Compositions and methods for coating medical implants |
US20050129769A1 (en) * | 2002-06-03 | 2005-06-16 | Barry Stephen E. | Polymeric articles for carrying therapeutic agents |
US20040034336A1 (en) * | 2002-08-08 | 2004-02-19 | Neal Scott | Charged liposomes/micelles with encapsulted medical compounds |
ES2686361T3 (en) * | 2002-10-29 | 2018-10-17 | Insmed Incorporated | Liposomes comprising an aminoglycoside for the treatment of lung infections |
US7718189B2 (en) | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
WO2004043507A1 (en) * | 2002-11-07 | 2004-05-27 | Carbon Medical Technologies, Inc. | Biocompatible medical device coatings |
US6992127B2 (en) | 2002-11-25 | 2006-01-31 | Ast Products, Inc. | Polymeric coatings containing a pH buffer agent |
US7597903B2 (en) * | 2002-12-02 | 2009-10-06 | Shenkar College Of Engineering And Design | Method and composition for producing catheters with antibacterial property |
US7488757B2 (en) | 2003-03-24 | 2009-02-10 | Becton, Dickinson And Company | Invisible antimicrobial glove and hand antiseptic |
US8048407B2 (en) * | 2003-04-24 | 2011-11-01 | Brent Vernon | In situ gelling self-reactive materials for embolization |
US20040254545A1 (en) * | 2003-06-16 | 2004-12-16 | Rider Dean Loller | Method and apparatus for extending feeding tube longevity |
JP4320572B2 (en) * | 2003-07-11 | 2009-08-26 | ソニー株式会社 | Signal processing apparatus and method, recording medium, and program |
CA2542512A1 (en) * | 2003-09-04 | 2005-03-17 | Nathan Ravi | Hydrogel nanocompsites for ophthalmic applications |
US20050074453A1 (en) * | 2003-10-02 | 2005-04-07 | Ferree Bret A. | Methods of preventing adhesions following laminectomies and other surgical procedures |
ATE524203T1 (en) * | 2003-11-03 | 2011-09-15 | Medtronic Inc | HYDROGEL FOR CELL-SPECIFIC INGROWTH |
US20050208095A1 (en) * | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
US20050112151A1 (en) * | 2003-11-20 | 2005-05-26 | Horng Liou L. | Skin adherent hydrogels |
EP1687043A2 (en) * | 2003-11-20 | 2006-08-09 | Angiotech International Ag | Electrical devices and anti-scarring agents |
WO2005051396A2 (en) * | 2003-11-25 | 2005-06-09 | Deltanoid Pharmaceuticals, Inc. | Methods for reducing body fat using vitamin d compounds |
WO2006002528A1 (en) * | 2004-06-30 | 2006-01-12 | Covalon Technologies Inc. | Non-adhesive hydrogels |
US7221982B2 (en) * | 2004-07-12 | 2007-05-22 | Cardiac Pacemakers, Inc. | Apparatus and method of coating implantable leads |
US8312836B2 (en) | 2004-09-28 | 2012-11-20 | Atrium Medical Corporation | Method and apparatus for application of a fresh coating on a medical device |
US8367099B2 (en) | 2004-09-28 | 2013-02-05 | Atrium Medical Corporation | Perforated fatty acid films |
US20090104254A1 (en) * | 2004-12-22 | 2009-04-23 | Rutgers, The State University Of New Jersey | Controlled Release Hydrogels |
WO2006079015A2 (en) * | 2005-01-21 | 2006-07-27 | Vertex Pharmaceuticals Incorporated | Quorum sensing modulators |
AU2005100176A4 (en) * | 2005-03-01 | 2005-04-07 | Gym Tv Pty Ltd | Garbage bin clip |
US8029482B2 (en) | 2005-03-04 | 2011-10-04 | C. R. Bard, Inc. | Systems and methods for radiographically identifying an access port |
JP5484674B2 (en) | 2005-03-04 | 2014-05-07 | シー・アール・バード・インコーポレーテッド | Access port and identification method |
US9474888B2 (en) | 2005-03-04 | 2016-10-25 | C. R. Bard, Inc. | Implantable access port including a sandwiched radiopaque insert |
US7947022B2 (en) | 2005-03-04 | 2011-05-24 | C. R. Bard, Inc. | Access port identification systems and methods |
RU2385711C2 (en) * | 2005-03-21 | 2010-04-10 | Лайфкэр Инновейшнз Пвт. Лтд. | Multilayer vesicular composition |
WO2006116613A1 (en) * | 2005-04-27 | 2006-11-02 | C.R. Bard, Inc. | Infusion apparatuses |
EP2308547B1 (en) | 2005-04-27 | 2014-09-17 | C.R. Bard, Inc. | High pressure access port with septum |
US10307581B2 (en) | 2005-04-27 | 2019-06-04 | C. R. Bard, Inc. | Reinforced septum for an implantable medical device |
EP1893130A4 (en) | 2005-06-17 | 2015-08-26 | Georgia Tech Res Inst | Coated microstructures and method of manufacture thereof |
US7919583B2 (en) * | 2005-08-08 | 2011-04-05 | Discovery Genomics, Inc. | Integration-site directed vector systems |
RU2444351C2 (en) * | 2005-09-01 | 2012-03-10 | Биолипокс Аб | Composition for treating rhinitis and related diseases and method for preparing it |
CA2626030A1 (en) | 2005-10-15 | 2007-04-26 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
CA2896083A1 (en) | 2005-12-08 | 2007-06-14 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
JP5819579B2 (en) * | 2006-01-13 | 2015-11-24 | サーモディクス,インコーポレイティド | Microparticles containing matrices for drug delivery |
US20070184085A1 (en) * | 2006-02-03 | 2007-08-09 | Boston Scientific Scimed, Inc. | Ultrasound activated medical device |
DE102006015271A1 (en) * | 2006-04-01 | 2007-10-11 | Lohmann & Rauscher Gmbh & Co. Kg | Biguanide-containing liposomes |
EP2037977A2 (en) * | 2006-06-28 | 2009-03-25 | SurModics, Inc. | Active agent eluting matrices with particulates |
US8747738B2 (en) * | 2006-08-15 | 2014-06-10 | Abbott Cardiovascular Systems Inc. | Sterilization methods for medical devices |
US9642986B2 (en) | 2006-11-08 | 2017-05-09 | C. R. Bard, Inc. | Resource information key for an insertable medical device |
US9265912B2 (en) | 2006-11-08 | 2016-02-23 | C. R. Bard, Inc. | Indicia informative of characteristics of insertable medical devices |
US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
CN103933606B (en) | 2006-12-15 | 2016-08-24 | 生命连结有限公司 | Gelatin-transglutaminase hemostatic dressings and encapsulant |
US20080181928A1 (en) * | 2006-12-22 | 2008-07-31 | Miv Therapeutics, Inc. | Coatings for implantable medical devices for liposome delivery |
EP1980277A1 (en) * | 2007-03-17 | 2008-10-15 | Peter Hildebrandt | Gastroenterological medical product, in particular stent for the bile duct or pancreatic duct |
US8093039B2 (en) * | 2007-04-10 | 2012-01-10 | The Trustees Of The Stevens Institute Of Technology | Surfaces differentially adhesive to eukaryotic cells and non-eukaryotic cells |
US20100196455A1 (en) | 2007-05-04 | 2010-08-05 | Transave, Inc. | Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof |
US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
DE102007039871A1 (en) * | 2007-08-21 | 2009-02-26 | Friedrich-Baur-Gmbh | Soft tissue implant with antibacterial effect |
DE602008005771D1 (en) * | 2007-08-27 | 2011-05-05 | Theravance Inc | DISUBSTITUTED ALKYL-8-AZABICYCLOÄ3.2.1ÜOKTAN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS |
CA2702183A1 (en) * | 2007-10-10 | 2009-04-16 | Miv Therapeutics Inc. | Lipid coatings for implantable medical devices |
US9579496B2 (en) | 2007-11-07 | 2017-02-28 | C. R. Bard, Inc. | Radiopaque and septum-based indicators for a multi-lumen implantable port |
US9308068B2 (en) | 2007-12-03 | 2016-04-12 | Sofradim Production | Implant for parastomal hernia |
EP2265293B1 (en) * | 2008-04-18 | 2015-11-04 | SurModics, Inc. | Coating systems for the controlled delivery of hydrophilic bioactive agents |
US20090285882A1 (en) * | 2008-04-22 | 2009-11-19 | Jochen Weiss | Stabilized Liposome Compositions and Related Methods of Use |
US9943614B2 (en) | 2008-06-17 | 2018-04-17 | Brigham Young University | Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods |
WO2009153751A2 (en) * | 2008-06-18 | 2009-12-23 | Lifebond Ltd | A method for enzymatic cross-linking of a protein |
CA2728186A1 (en) * | 2008-06-18 | 2009-12-23 | Lifebond Ltd | Methods and devices for use with sealants |
JP5450612B2 (en) * | 2008-06-18 | 2014-03-26 | ライフボンド リミテッド | Improved cross-linking composition |
US9242026B2 (en) | 2008-06-27 | 2016-01-26 | Sofradim Production | Biosynthetic implant for soft tissue repair |
WO2010008564A2 (en) * | 2008-07-16 | 2010-01-21 | Recombinetics | Plaice dna transposon system |
US20100070013A1 (en) * | 2008-09-18 | 2010-03-18 | Medtronic Vascular, Inc. | Medical Device With Microsphere Drug Delivery System |
EP2346553B1 (en) | 2008-10-31 | 2022-01-19 | C.R. Bard, Inc. | Systems and methods for identifying an access port |
US11890443B2 (en) | 2008-11-13 | 2024-02-06 | C. R. Bard, Inc. | Implantable medical devices including septum-based indicators |
US8932271B2 (en) | 2008-11-13 | 2015-01-13 | C. R. Bard, Inc. | Implantable medical devices including septum-based indicators |
US20120093914A1 (en) * | 2008-11-24 | 2012-04-19 | Moma Therapeutics | Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration |
US10314935B2 (en) | 2009-01-07 | 2019-06-11 | Entrotech Life Sciences, Inc. | Chlorhexidine-containing antimicrobial laminates |
US8709473B1 (en) * | 2009-01-28 | 2014-04-29 | Abbott Cardiovascular Systems Inc. | Method of targeting hydrophobic drugs to vascular lesions |
US20100239627A1 (en) * | 2009-03-20 | 2010-09-23 | Wilson Kurt Whitekettle | Quarternary ammonium salts delivery systems |
US20100239626A1 (en) * | 2009-03-20 | 2010-09-23 | Wilson Kurt Whitekettle | Propanediol delivery systems |
US20100239630A1 (en) * | 2009-03-20 | 2010-09-23 | Wilson Kurt Whitekettle | Phosphonium salts delivery systems |
US20100239651A1 (en) * | 2009-03-20 | 2010-09-23 | Wilson Kurt Whitekettle | Nitrilopropionamide delivery systems |
US20100239650A1 (en) * | 2009-03-20 | 2010-09-23 | Wilson Kurt Whitekettle | Isothiazolin biodelivery systems |
US20100249783A1 (en) * | 2009-03-24 | 2010-09-30 | Warsaw Orthopedic, Inc. | Drug-eluting implant cover |
US20100247600A1 (en) * | 2009-03-24 | 2010-09-30 | Warsaw Orthopedic, Inc. | Therapeutic drug eluting implant cover and method of making the same |
US9414864B2 (en) | 2009-04-15 | 2016-08-16 | Warsaw Orthopedic, Inc. | Anterior spinal plate with preformed drug-eluting device affixed thereto |
US9078712B2 (en) * | 2009-04-15 | 2015-07-14 | Warsaw Orthopedic, Inc. | Preformed drug-eluting device to be affixed to an anterior spinal plate |
WO2010140163A2 (en) * | 2009-06-02 | 2010-12-09 | Concept Medical Inc. | Rejuvenating coronary artery by improving blood flow with the help of insertion of nano-balls (encapsulated nanoparticles) containing therapeutic agents by non implantable device for tissues and thereby providing in tissue release to address the required cell cycle |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
FR2949688B1 (en) | 2009-09-04 | 2012-08-24 | Sofradim Production | FABRIC WITH PICOTS COATED WITH A BIORESORBABLE MICROPOROUS LAYER |
US8795727B2 (en) | 2009-11-09 | 2014-08-05 | Spotlight Technology Partners Llc | Fragmented hydrogels |
CN106913902A (en) | 2009-11-09 | 2017-07-04 | 聚光灯技术合伙有限责任公司 | Polysaccharide based aquagel |
JP2013510652A (en) | 2009-11-17 | 2013-03-28 | シー・アール・バード・インコーポレーテッド | Overmolded access port including locking feature and identification feature |
BR112012015029A2 (en) | 2009-12-22 | 2017-06-27 | Lifebond Ltd | cross-linked matrix, method for controlling the formation of a matrix, method or matrix, method for sealing a tissue against leakage of a body fluid, hemostatic agent or surgical seal, composition for sealing a wound, use of the composition, composition for a delivery vehicle drug composition, tissue engineering composition, and method for modifying a composition |
CN102782064B (en) | 2009-12-23 | 2015-04-15 | 帝斯曼知识产权资产管理有限公司 | Method to activate silicone rubber surfaces |
US20120028335A1 (en) | 2010-07-28 | 2012-02-02 | Life Technologies Corporation | Anti-viral azide-containing compounds |
CN103237546B (en) | 2010-07-28 | 2016-06-08 | 生命科技公司 | The antiviral compound that contains azide |
ES2567174T3 (en) | 2010-08-05 | 2016-04-20 | Lifebond Ltd | Dry composition in dressings and wound adhesives |
US8753608B2 (en) | 2010-08-24 | 2014-06-17 | Canon Kabushiki Kaisha | Complex and contrast agent for photoimaging using the same |
US20140086975A1 (en) | 2010-10-15 | 2014-03-27 | Rutgers, The State University Of New Jersey | Hydrogel formulation for dermal and ocular delivery |
USD682416S1 (en) | 2010-12-30 | 2013-05-14 | C. R. Bard, Inc. | Implantable access port |
USD676955S1 (en) | 2010-12-30 | 2013-02-26 | C. R. Bard, Inc. | Implantable access port |
FR2972626B1 (en) | 2011-03-16 | 2014-04-11 | Sofradim Production | PROSTHETIC COMPRISING A THREE-DIMENSIONAL KNIT AND ADJUSTED |
WO2012155048A1 (en) * | 2011-05-11 | 2012-11-15 | Wisconsin Alumni Research Foundation | Liposome-encapsulated hydrogels for use in a drug delivery system |
FR2977790B1 (en) | 2011-07-13 | 2013-07-19 | Sofradim Production | PROSTHETIC FOR UMBILIC HERNIA |
FR2977789B1 (en) | 2011-07-13 | 2013-07-19 | Sofradim Production | PROSTHETIC FOR UMBILIC HERNIA |
ES2725784T3 (en) * | 2011-07-20 | 2019-09-27 | Univ Brigham Young | Hydrophobic ceragenin compounds and devices incorporating it |
US8932614B2 (en) | 2011-08-25 | 2015-01-13 | Paul B. Savage | Incorporation of particulate ceragenins in polymers |
US9694019B2 (en) | 2011-09-13 | 2017-07-04 | Brigham Young University | Compositions and methods for treating bone diseases and broken bones |
CN104080459B (en) | 2011-09-13 | 2018-07-03 | 布莱阿姆青年大学 | For treating the composition of bone disease and knochenbruch |
CA2848567C (en) | 2011-09-13 | 2020-03-24 | Brigham Young University | Products for healing of tissue wounds |
US9603859B2 (en) | 2011-09-13 | 2017-03-28 | Brigham Young University | Methods and products for increasing the rate of healing of tissue wounds |
WO2013046058A2 (en) | 2011-09-30 | 2013-04-04 | Sofradim Production | Reversible stiffening of light weight mesh |
JP6111013B2 (en) * | 2011-10-30 | 2017-04-05 | 株式会社セルシード | Tendon cell sheet and manufacturing method thereof |
CA2859325A1 (en) | 2011-12-21 | 2013-07-25 | Brigham Young University | Oral care compositions |
FR2985271B1 (en) | 2011-12-29 | 2014-01-24 | Sofradim Production | KNITTED PICOTS |
FR2985170B1 (en) | 2011-12-29 | 2014-01-24 | Sofradim Production | PROSTHESIS FOR INGUINAL HERNIA |
SG11201404361UA (en) | 2012-01-26 | 2014-09-26 | Life Technologies Corp | Methods for increasing the infectivity of viruses |
US9533063B1 (en) | 2012-03-01 | 2017-01-03 | Brigham Young University | Aerosols incorporating ceragenin compounds and methods of use thereof |
US10039285B2 (en) | 2012-05-02 | 2018-08-07 | Brigham Young University | Ceragenin particulate materials and methods for making same |
CA2870860C (en) | 2012-05-21 | 2021-07-27 | Insmed Incorporated | Systems for treating pulmonary infections |
FR2994185B1 (en) | 2012-08-02 | 2015-07-31 | Sofradim Production | PROCESS FOR THE PREPARATION OF A POROUS CHITOSAN LAYER |
FR2995778B1 (en) | 2012-09-25 | 2015-06-26 | Sofradim Production | ABDOMINAL WALL REINFORCING PROSTHESIS AND METHOD FOR MANUFACTURING THE SAME |
FR2995779B1 (en) | 2012-09-25 | 2015-09-25 | Sofradim Production | PROSTHETIC COMPRISING A TREILLIS AND A MEANS OF CONSOLIDATION |
FR2995788B1 (en) | 2012-09-25 | 2014-09-26 | Sofradim Production | HEMOSTATIC PATCH AND PREPARATION METHOD |
EP2900174B1 (en) | 2012-09-28 | 2017-04-12 | Sofradim Production | Packaging for a hernia repair device |
AU2013331136B2 (en) | 2012-10-17 | 2016-05-12 | Brigham Young University | Treatment and prevention of mastitis |
RU2675859C2 (en) | 2012-11-29 | 2018-12-25 | Инсмед Инкорпорейтед | Stabilised vancomycin formulations |
AU2014203882B2 (en) | 2013-01-07 | 2016-06-23 | Brigham Young University | Methods for reducing cellular proliferation and treating certain diseases |
US10568893B2 (en) | 2013-03-15 | 2020-02-25 | Brigham Young University | Methods for treating inflammation, autoimmune disorders and pain |
KR102282183B1 (en) | 2013-03-15 | 2021-07-26 | 브라이엄 영 유니버시티 | Methods for treating inflammation, autoimmune disorders and pain |
US11524015B2 (en) | 2013-03-15 | 2022-12-13 | Brigham Young University | Methods for treating inflammation, autoimmune disorders and pain |
US9387215B2 (en) | 2013-04-22 | 2016-07-12 | Brigham Young University | Animal feed including cationic cholesterol additive and related methods |
FR3006578B1 (en) | 2013-06-07 | 2015-05-29 | Sofradim Production | PROSTHESIS BASED ON TEXTILE FOR LAPAROSCOPIC PATHWAY |
FR3006581B1 (en) | 2013-06-07 | 2016-07-22 | Sofradim Production | PROSTHESIS BASED ON TEXTILE FOR LAPAROSCOPIC PATHWAY |
US11690855B2 (en) | 2013-10-17 | 2023-07-04 | Brigham Young University | Methods for treating lung infections and inflammation |
US20150203527A1 (en) | 2014-01-23 | 2015-07-23 | Brigham Young University | Cationic steroidal antimicrobials |
CN105142688B (en) | 2014-02-04 | 2018-01-19 | 艾博特心血管系统公司 | Cause novolimus and drug delivery stent or support member of the coating with minimum bonded amount with the coating based on novolimus and lactide |
CA2844321C (en) | 2014-02-27 | 2021-03-16 | Brigham Young University | Cationic steroidal antimicrobial compounds |
US9867836B2 (en) | 2014-03-13 | 2018-01-16 | Brigham Young University | Lavage and/or infusion using CSA compounds for increasing fertility in a mammal |
US10220045B2 (en) | 2014-03-13 | 2019-03-05 | Brigham Young University | Compositions and methods for forming stabilized compositions with reduced CSA agglomeration |
US9931350B2 (en) | 2014-03-14 | 2018-04-03 | Brigham Young University | Anti-infective and osteogenic compositions and methods of use |
WO2015161302A1 (en) | 2014-04-18 | 2015-10-22 | Entrotech Life Sciences, Inc. | Methods of processing chlorhexidine-containing polymerizable compositions and antimicrobial articles formed thereby |
US9686966B2 (en) | 2014-04-30 | 2017-06-27 | Brigham Young University | Methods and apparatus for cleaning or disinfecting a water delivery system |
ES2926985T3 (en) | 2014-05-15 | 2022-10-31 | Insmed Inc | Methods for treating nontuberculous mycobacterial lung infections |
US10238665B2 (en) | 2014-06-26 | 2019-03-26 | Brigham Young University | Methods for treating fungal infections |
US10441595B2 (en) | 2014-06-26 | 2019-10-15 | Brigham Young University | Methods for treating fungal infections |
US10227376B2 (en) | 2014-08-22 | 2019-03-12 | Brigham Young University | Radiolabeled cationic steroid antimicrobials and diagnostic methods |
EP3000433B1 (en) | 2014-09-29 | 2022-09-21 | Sofradim Production | Device for introducing a prosthesis for hernia treatment into an incision and flexible textile based prosthesis |
EP3000432B1 (en) | 2014-09-29 | 2022-05-04 | Sofradim Production | Textile-based prosthesis for treatment of inguinal hernia |
IL234929B (en) * | 2014-10-01 | 2021-01-31 | Yeda Res & Dev | Liposomes-containing antifouling compositions and uses thereof |
US10155788B2 (en) | 2014-10-07 | 2018-12-18 | Brigham Young University | Cationic steroidal antimicrobial prodrug compositions and uses thereof |
EP3029189B1 (en) | 2014-12-05 | 2021-08-11 | Sofradim Production | Prosthetic porous knit, method of making same and hernia prosthesis |
US9757774B2 (en) * | 2015-01-15 | 2017-09-12 | MyExposome, Inc. | Passive sampling devices |
EP3059255B1 (en) | 2015-02-17 | 2020-05-13 | Sofradim Production | Method for preparing a chitosan-based matrix comprising a fiber reinforcement member |
WO2016172543A1 (en) | 2015-04-22 | 2016-10-27 | Savage Paul B | Methods for the synthesis of ceragenins |
WO2016172553A1 (en) | 2015-04-22 | 2016-10-27 | Savage Paul B | Methods for the synthesis of ceragenins |
EP3085337B1 (en) | 2015-04-24 | 2022-09-14 | Sofradim Production | Prosthesis for supporting a breast structure |
US10126298B2 (en) | 2015-05-04 | 2018-11-13 | Arman Nabatian | Hydrogels containing embedded substrates for targeted binding of molecules |
JP6816121B2 (en) * | 2015-05-14 | 2021-01-20 | アソシエーション フォー ジ アドバンスメント オブ ティシュー エンジニアリング アンド セル ベイスト テクノロジーズ アンド セラピーズ(エイ4テック)− アソシアソンAssociation For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies (A4Tec) − Associacao | Ureteral stents, methods and their use |
US9434759B1 (en) | 2015-05-18 | 2016-09-06 | Brigham Young University | Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds |
EP3322365A4 (en) * | 2015-05-22 | 2019-04-17 | Orthobond, Inc. | Methods, compositions and techniques for polydimethylsiloxane surface modifications |
ES2676072T3 (en) | 2015-06-19 | 2018-07-16 | Sofradim Production | Synthetic prosthesis comprising a knitted fabric and a non-porous film and method of forming it |
SG10201913355RA (en) | 2015-09-17 | 2020-02-27 | Histide Ag | Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof |
RU2617062C1 (en) * | 2015-10-22 | 2017-04-19 | Акционерное общество "Медсил" | Plastic endoprosthesis for stenting pancreatic ducts |
EP3195830B1 (en) | 2016-01-25 | 2020-11-18 | Sofradim Production | Prosthesis for hernia repair |
US10792477B2 (en) | 2016-02-08 | 2020-10-06 | Orbusneich Medical Pte. Ltd. | Drug eluting balloon |
US20210196932A1 (en) * | 2016-02-08 | 2021-07-01 | Orbusneich Medical, Inc. | Drug Eluting Balloon |
US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
RU2624535C1 (en) * | 2016-10-14 | 2017-07-04 | Акционерное общество "Медсил" | Plastic endoprosthesis for stenting pancreatic ducts |
EP3312325B1 (en) | 2016-10-21 | 2021-09-22 | Sofradim Production | Method for forming a mesh having a barbed suture attached thereto and the mesh thus obtained |
US11529391B2 (en) * | 2017-01-09 | 2022-12-20 | The Board Of Trustees Of The Leland Stanford Junior University | Reversing deficient hedgehog signaling restores deficient skeletal regeneration |
US10959433B2 (en) | 2017-03-21 | 2021-03-30 | Brigham Young University | Use of cationic steroidal antimicrobials for sporicidal activity |
EP3398554A1 (en) | 2017-05-02 | 2018-11-07 | Sofradim Production | Prosthesis for inguinal hernia repair |
US20200276362A1 (en) * | 2017-09-29 | 2020-09-03 | Bard Shannon Limited | Composition and method for controlled drug release from a tissue |
WO2019191627A1 (en) | 2018-03-30 | 2019-10-03 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
EP3653171A1 (en) | 2018-11-16 | 2020-05-20 | Sofradim Production | Implants suitable for soft tissue repair |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4749585A (en) * | 1986-04-11 | 1988-06-07 | University Of Medicine And Dentistry Of New Jersey | Antibiotic bonded prosthesis and process for producing same |
WO1991009616A1 (en) * | 1989-12-22 | 1991-07-11 | Yale University | Quinolone antibiotics encapsulated in lipid vesicles |
US5575815A (en) * | 1988-08-24 | 1996-11-19 | Endoluminal Therapeutics, Inc. | Local polymeric gel therapy |
CA2181390A1 (en) * | 1995-07-18 | 1997-01-19 | Pankaj Modi | Phospholipid formulations |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4442133A (en) * | 1982-02-22 | 1984-04-10 | Greco Ralph S | Antibiotic bonding of vascular prostheses and other implants |
FR2668063A1 (en) * | 1990-10-17 | 1992-04-24 | Fabre Pierre Cosmetique | LIPOSOMES OF THERMAL WATER STABILIZED IN A DNA GEL. |
EP0489206B1 (en) * | 1990-12-04 | 1997-02-19 | Zenith Technology Corporation Limited | Synthetic skin substitutes |
CA2097163C (en) * | 1992-06-01 | 2002-07-30 | Marianna Foldvari | Topical patch for liposomal drug delivery system |
US5863556A (en) * | 1993-08-20 | 1999-01-26 | Euro-Celtique, S.A. | Preparations for the external application of antiseptic agents and/or agents promoting the healing of wounds |
US5433745A (en) * | 1993-10-13 | 1995-07-18 | Allergan, Inc. | Corneal implants and methods for producing same |
EP0754064B1 (en) * | 1994-04-08 | 2003-05-28 | Atrix Laboratories, Inc. | An adjunctive polymer system for use with medical device |
US5741516A (en) * | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
-
1997
- 1997-04-15 US US08/843,342 patent/US6132765A/en not_active Expired - Fee Related
-
1998
- 1998-04-15 WO PCT/CA1998/000351 patent/WO1998046287A2/en active IP Right Grant
- 1998-04-15 AU AU70198/98A patent/AU736584B2/en not_active Ceased
- 1998-04-15 JP JP54333498A patent/JP2001523124A/en active Pending
- 1998-04-15 AT AT98916701T patent/ATE305803T1/en not_active IP Right Cessation
- 1998-04-15 CA CA002286644A patent/CA2286644C/en not_active Expired - Fee Related
- 1998-04-15 DE DE69831802T patent/DE69831802T2/en not_active Expired - Lifetime
- 1998-04-15 CA CA002634700A patent/CA2634700A1/en not_active Abandoned
- 1998-04-15 EP EP98916701A patent/EP0984798B1/en not_active Expired - Lifetime
-
1999
- 1999-10-05 US US09/412,584 patent/US6228393B1/en not_active Expired - Fee Related
-
2001
- 2001-03-28 US US09/818,649 patent/US6475516B2/en not_active Expired - Fee Related
- 2001-05-07 US US09/849,481 patent/US20020051812A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4749585A (en) * | 1986-04-11 | 1988-06-07 | University Of Medicine And Dentistry Of New Jersey | Antibiotic bonded prosthesis and process for producing same |
US5575815A (en) * | 1988-08-24 | 1996-11-19 | Endoluminal Therapeutics, Inc. | Local polymeric gel therapy |
WO1991009616A1 (en) * | 1989-12-22 | 1991-07-11 | Yale University | Quinolone antibiotics encapsulated in lipid vesicles |
CA2181390A1 (en) * | 1995-07-18 | 1997-01-19 | Pankaj Modi | Phospholipid formulations |
Non-Patent Citations (1)
Title |
---|
"Liposomal-Hydrogel Delivery of Ciprofloxacin at Catheter Surfaces", M.W. MITTELMAN ET AL, 37th INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, TORONTO, CANADA, SEPTEMBER 28-OCTOBER 1, 1997, Abstracts 37 (0), page 325 XP002080599 * |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407671B2 (en) | 1998-03-31 | 2008-08-05 | Boston Scientific Scimed, Inc. | Temperature controlled solute delivery system |
WO1999049908A1 (en) * | 1998-03-31 | 1999-10-07 | University Of Cincinnati | Temperature controlled solute delivery system |
WO2001015750A1 (en) * | 1999-08-27 | 2001-03-08 | Department Of National Defence | Hydrogel wound dressing containing liposome-encapsulated therapeutic agent |
WO2001089595A1 (en) * | 2000-05-24 | 2001-11-29 | Research & Development Center Of Bioengineering Gmbh | Polymer surface having biologically active properties and methods for the production thereof |
KR100994543B1 (en) * | 2001-02-16 | 2010-11-16 | 아스텔라스세이야쿠 가부시키가이샤 | 506 implants with fk506 |
US8840927B2 (en) | 2001-02-28 | 2014-09-23 | Covalon Technologies Inc. | Method of making anti-microbial polymeric surfaces |
WO2002070022A3 (en) * | 2001-02-28 | 2003-01-16 | Valerio Ditizio | Method of making anti-microbial polymeric surfaces |
US6808738B2 (en) | 2001-02-28 | 2004-10-26 | Uroteq Inc. | Method of making anti-microbial polymeric surfaces |
WO2002070022A2 (en) * | 2001-02-28 | 2002-09-12 | Uroteq Inc. | Method of making anti-microbial polymeric surfaces |
AU2002235694B2 (en) * | 2001-02-28 | 2007-06-14 | Covalon Technologies Inc. | Method of making anti-microbial polymeric surfaces |
WO2002074355A1 (en) * | 2001-03-15 | 2002-09-26 | Dot Gmbh | Calcium phosphate materials containing active ingredients |
US8025901B2 (en) | 2001-04-23 | 2011-09-27 | Wisconsin Alumni Research Foundation | Bifunctional-modified hydrogels |
US7615593B2 (en) | 2001-04-23 | 2009-11-10 | Wisconsin Alumni Research Foundation | Bifunctional-modified hydrogels |
WO2003061715A1 (en) * | 2002-01-22 | 2003-07-31 | Pharmacia & Upjohn Company | Infection-resistant medical devices |
CN1301751C (en) * | 2002-01-22 | 2007-02-28 | 法玛西雅厄普约翰美国公司 | Infection-resistant medical devices |
US7322965B2 (en) | 2002-01-22 | 2008-01-29 | Pharmacia & Upjohn Company | Infection-resistant medical devices |
EP1553899A2 (en) * | 2002-10-22 | 2005-07-20 | The Biomerix Corporation | Method and system for intravesicular delivery of therapeutic agents |
EP1553899A4 (en) * | 2002-10-22 | 2006-10-25 | Method and system for intravesicular delivery of therapeutic agents | |
US11793912B2 (en) | 2004-09-28 | 2023-10-24 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US10814043B2 (en) | 2004-09-28 | 2020-10-27 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US10869902B2 (en) | 2004-09-28 | 2020-12-22 | Atrium Medical Corporation | Cured gel and method of making |
US10792312B2 (en) | 2004-09-28 | 2020-10-06 | Atrium Medical Corporation | Barrier layer |
US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
US10772995B2 (en) | 2004-09-28 | 2020-09-15 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US10016465B2 (en) | 2004-09-28 | 2018-07-10 | Atrium Medical Corporation | Cured gel and method of making |
US9801913B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Barrier layer |
US9682175B2 (en) | 2004-09-28 | 2017-06-20 | Atrium Medical Corporation | Coating material and medical device system including same |
US8361501B2 (en) | 2004-09-30 | 2013-01-29 | Covalon Technologies, Inc. | Non-adhesive elastic gelatin matrices |
US8628800B2 (en) | 2004-09-30 | 2014-01-14 | Covalon Technologies, Inc. | Non-adhesive elastic gelatin matrices |
US8354123B2 (en) | 2004-09-30 | 2013-01-15 | Covalon Technologies Inc. | Non-adhesive elastic gelatin matrices |
US9844611B2 (en) | 2005-09-28 | 2017-12-19 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US11083823B2 (en) | 2005-09-28 | 2021-08-10 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
WO2007110767A2 (en) * | 2006-03-24 | 2007-10-04 | Universita' Degli Studi Di Pavia | Interactive dressings for treatment of dermatological diseases |
WO2007110767A3 (en) * | 2006-03-24 | 2008-02-07 | Univ Pavia | Interactive dressings for treatment of dermatological diseases |
US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
US9592324B2 (en) | 2006-11-06 | 2017-03-14 | Atrium Medical Corporation | Tissue separating device with reinforced support for anchoring mechanisms |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US10285964B2 (en) | 2009-03-10 | 2019-05-14 | Atrium Medical Corporation | Fatty-acid based particles |
US11166929B2 (en) | 2009-03-10 | 2021-11-09 | Atrium Medical Corporation | Fatty-acid based particles |
US10322213B2 (en) | 2010-07-16 | 2019-06-18 | Atrium Medical Corporation | Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
US11097035B2 (en) | 2010-07-16 | 2021-08-24 | Atrium Medical Corporation | Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
US10888617B2 (en) | 2012-06-13 | 2021-01-12 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
Also Published As
Publication number | Publication date |
---|---|
US6132765A (en) | 2000-10-17 |
US6228393B1 (en) | 2001-05-08 |
WO1998046287A3 (en) | 1999-02-11 |
AU736584B2 (en) | 2001-08-02 |
JP2001523124A (en) | 2001-11-20 |
US20020009485A1 (en) | 2002-01-24 |
EP0984798A2 (en) | 2000-03-15 |
DE69831802T2 (en) | 2006-07-06 |
CA2286644C (en) | 2008-10-07 |
EP0984798B1 (en) | 2005-10-05 |
DE69831802D1 (en) | 2005-11-10 |
AU7019898A (en) | 1998-11-11 |
CA2286644A1 (en) | 1998-10-22 |
US6475516B2 (en) | 2002-11-05 |
US20020051812A1 (en) | 2002-05-02 |
CA2634700A1 (en) | 1998-10-22 |
ATE305803T1 (en) | 2005-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0984798B1 (en) | Drug delivery via therapeutic hydrogels | |
DiTizio et al. | A liposomal hydrogel for the prevention of bacterial adhesion to catheters | |
ES2258482T3 (en) | ELECTROPOLIMERIZABLE MONOMERS AND POLYMERIC COATINGS OF IMPLANTABLE DEVICES. | |
US5821343A (en) | Oxidative method for attachment of biomolecules to surfaces of medical devices | |
US5945319A (en) | Periodate oxidative method for attachment of biomolecules to medical device surfaces | |
US7794751B2 (en) | Medicament incorporation matrix | |
JP2005505321A (en) | Constructs and techniques for local treatment of restenosis | |
AU2001281304A1 (en) | Medicament incorporation matrix | |
JP2003519650A (en) | Polymer blends as biodegradable matrices for producing biocomposites | |
EP2002847A1 (en) | Drug-releasing polyelectrolyte coating, method for forming a drug-releasing polyelectrolyte coating, and implantable device | |
US6961610B2 (en) | Branched polyethylene oxide terminated biomedical polymers and their use in biomedical devices | |
EP2416815B1 (en) | Ligand-specific inhibition of attachment of immune cells to implantable biomaterials | |
Ghosh et al. | Recent Development in Polyurethanes for Biomedical Applications | |
US20210178129A1 (en) | Controlled Release of a Hydrophilic Agent from a Coated Surface | |
Ngambenjawong et al. | Layer-by-layer nanocoating of chlorophene-loaded polymeric micelles on silicone catheters | |
Tran et al. | Sustained Release of Antimicrobial Drugs from Graphene Oxide Immobilized Titanium Surfaces for the Enhanced Antibacterial Activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 1998 543334 Country of ref document: JP Kind code of ref document: A Ref document number: 2286644 Country of ref document: CA Kind code of ref document: A Ref document number: 2286644 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 70198/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998916701 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998916701 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 70198/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998916701 Country of ref document: EP |